J2993 Reteplase Injection HCPCS Reimbursement

HCPCS Level II code J2993 denotes the injection of reteplase 18.1 mg, a thrombolytic agent used for systemic fibrinolysis in acute cardiovascular events. Nationally, accurate coding for thrombolytic agents matters for clinical documentation, hospital billing workflows, and payer adjudication because these agents are high-cost, time-sensitive therapies often administered in acute-care settings.

This analysis covers coverage and billing practice across major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J2993 is used in clinical workflows, typical sites of service, and the implications for charge capture and claims processing. The publication also summarizes common billing modifiers and payer considerations, offers benchmarking context where available, and flags policy elements that affect reimbursement and prior authorization.

Intended for revenue-cycle professionals, hospital billing managers, and clinical coders, the report provides practical context on where J2993 fits within acute-care medication administration, how payers typically approach thrombolytic agent claims, and what operational areas—such as documentation and service-line coding—warrant attention.

Billing Code Overview

HCPCS Level II code J2993 describes an injection of reteplase, 18.1 mg. This code represents a single-dose parenteral administration of the thrombolytic agent reteplase for systemic fibrinolysis.

Service type: Medication administration via injection/IV thrombolytic therapy
Typical site of service: Hospital inpatient or emergency department settings, including cardiac catheterization labs and acute care units where thrombolytic therapy is delivered

Clinical Context

A 62-year-old male presents to the emergency department within 3 hours of sudden-onset chest pain, diaphoresis, and shortness of breath. Initial evaluation with electrocardiogram demonstrates ST-segment elevation consistent with an acute ST-elevation myocardial infarction (STEMI). Troponin is elevated. The interventional cardiology team determines the patient is a candidate for pharmacologic thrombolysis due to anticipated delay to percutaneous coronary intervention or as adjunctive therapy when reteplase is indicated. The billable product J2993 (Injection, reteplase, 18.1 mg) is administered intravenously in the acute care setting under continuous cardiac monitoring.

Workflow steps:

Triage and rapid cardiac ischemia evaluation with ECG and cardiac biomarkers.
Informed consent obtained from patient or proxy for thrombolytic therapy when possible.
Baseline labs (complete blood count, coagulation studies, basic metabolic panel) and assessment for contraindications to thrombolysis.
Administration of concurrent antiplatelet and anticoagulant therapy per institution protocol.
Dosing and administration of J2993 in the ED, observation area, or cardiac catheterization lab with continuous telemetry and hemodynamic monitoring.
Post-administration monitoring for reperfusion, bleeding complications, and neurological changes; transfer to intensive care or chest pain unit as indicated.

Typical site of service: hospital inpatient, emergency department, or observation unit. Typical patient scenario: acute STEMI or other acute thrombotic occlusion where reteplase is clinically indicated and supplied as a single-use injectable product represented by .

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier specified (default)	Used when no other specific modifier applies to the service.
`22`	Increased procedural services	Use when the service required substantially greater effort than usual (e.g., complex resuscitation or complicated administration circumstances).
`23`	Unusual anesthesia	Applied when general anesthesia is administered for an otherwise non‑anesthesia service related to the thrombosis management (rare for reteplase infusion).
`52`	Reduced services	Use if the full reteplase dose or service was partially provided or discontinued for clinical reasons.
`53`	Discontinued procedure	Applied when administration is started but halted due to patient instability or adverse reaction.
`62`	Two surgeons	Use when two qualified clinicians are required for a complex vascular procedure related to thrombolytic management.
`78`	Unplanned return to the operating/procedure room by the same physician following initial procedure	Use if the patient requires urgent re-intervention related to bleeding or thrombosis after thrombolytic therapy.
`80`	Assistant surgeon	Applied when an assistant surgeon participates in a related invasive procedure.
`82`	Assistant surgeon (when a qualified resident is not available)	Applied similarly when an assistant surgeon is needed and no resident is available.
`JW`	Drug discarded/not administered to any patient	Use when part of the single-use vial labeled under `J2993` is discarded and must be reported per payor policy.
`JZ`	No drug administered from single-dose vial	Use if the drug was not administered after being prepared.
`QX`	Ordering/servicing clinician modifier (laboratory context)	Rarely used; may apply for coordination when multiple clinicians are involved in testing associated with thrombolytic therapy.
`QY`	Ordering clinician (lab)	Similar limited use for lab ordering relationships.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for Medicare Part B	Use when such clinicians provide the billed service within their scope and Medicare-specific rules apply.

Taxonomy Code	Specialty	Notes
`207RC0000X`	Cardiovascular Disease (Cardiologist)	Interventional and non-interventional cardiologists commonly order and oversee thrombolytic therapy.
`207RH0000X`	Interventional Cardiology	Specialists who perform PCI and coordinate reperfusion therapies; may administer or supervise reteplase use.
`207LA0401X`	Emergency Medicine	Emergency physicians initiate thrombolytic therapy in the ED and manage acute administration and monitoring.
`163W00000X`	Critical Care Medicine	Intensivists manage post-thrombolysis care in ICU settings for hemodynamic instability and complications.
`364S00000X`	Hospitalist/Internal Medicine	Hospitalists coordinate inpatient monitoring and follow-up after acute reperfusion therapy.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`I21.09`	ST elevation (STEMI) myocardial infarction of other anterior wall	Primary indication for urgent thrombolysis when PCI is not immediately available.
`I21.3`	ST elevation (STEMI) myocardial infarction of unspecified site	General STEMI code applicable when reteplase is used for acute reperfusion.
`I21.01`	ST elevation (STEMI) myocardial infarction of left main coronary artery	Severe STEMI presentation where thrombolytic therapy may be considered in emergent settings.
`I22.0`	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Used if reinfarction occurs and additional thrombolytic consideration is needed.
`I24.8`	Other acute ischemic heart diseases	Used for other acute ischemic presentations where fibrinolytic therapy could be considered.
`I63.9`	Cerebral infarction, unspecified	Thrombolytics like reteplase are primarily used for myocardial infarction, not ischemic stroke; inclusion here is for differential emergent thrombolytic considerations but is not a standard indication for `J2993`.
`I26.9`	Pulmonary embolism without acute cor pulmonale	Massive pulmonary embolism can be an indication for systemic thrombolysis; reteplase may be considered depending on protocol.
`T46.4X5A`	Adverse effect of antithrombotic and thrombolytic drugs, initial encounter	Relevant for coding complications related to reteplase administration.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`92920`	Percutaneous transluminal coronary thrombectomy, including intracoronary agent, when performed; single vessel	Often performed if pharmacologic thrombolysis with `J2993` is insufficient or as a complementary revascularization procedure.
`92928`	Percutaneous coronary intervention, with stent; single major coronary artery or branch	May follow thrombolytic therapy if coronary angiography demonstrates a lesion requiring PCI.
`93000`	Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report	Performed before and after thrombolytic administration to document ischemia and reperfusion changes.
`36415`	Collection of venous blood by venipuncture	Baseline and follow-up laboratory testing (coagulation studies, CBC, chemistry) required around thrombolytic administration.
`99291`	Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes	Used if patient requires critical care services during or immediately after administration of `J2993` for monitoring and management of complications.

OpenPayer

Summary & Overview

HCPCS Level II J2993: Injection of Reteplase, 18.1 mg